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Abstract. In this study, by using different techniques (i.e.
Northern blot hybridization, RT-PCR and Southern blot
hybridization) on various normal rat tissues, we were able to
identify liver, kidney, heart, small intestine, brain, spleen,
stomach and prostate as tissues in which the ApoH gene is
transcribed. Moreover, for some of these tissues, by in situ
hybridization, we found a specific localization of apoH
transcripts. For instance epithelial cells of the bile ducts in
liver and of the proximal tubules in kidney are the major sites
of apoH synthesis. Our data suggest that some of the different
physiological roles proposed for apoH could correlate with
its direct expression, while others could correlate with its
absorption from bloodstream or adjacent cells. 
Introduction
Apolipoprotein H (apoH, named also ß-2-glycoprotein I) is a
50-kDa protein present in plasma both in free form and in
combination with lipoprotein particles (1,2). It consists of
four CCD (Complement Control Domain) modules (3) and a
fifth CCD-like domain carrying a lysine rich loop, responsible
for electrostatic interactions with anionic phospholipids, and
a hydrophobic loop able to enter the hydrophobic core of a
membrane (4). The crystal structure has revealed a fish hook-
like shape (5,6).
The physiological role of apoH remains unknown. In vitro
data demonstrated the ability of apoH to bind to anionic
surfaces, such as anionic phospholipids, heparin, DNA,
mitochondria and oxidized LDL (7-10). 
Considerable interest has been given to the pathological
properties of apoH. One aspect is that antiphospholipid
antibodies, present in plasma of patients with antiphospholipid
syndrome and other autoimmune diseases, do not bind to
phospholipids, while they bind to apoH when it forms a
complex with the acidic phospholipids and cardiolipin or is
immobilized on negatively charged surfaces (11-14). Another
pathological aspect of apoH relates to the high urinary
excretion of the protein in patients with Fanconi syndrome
(15). 
Different physiological activities have been attributed to
apoH, such as a possible role in the coagulation pathway,
exhibiting an inhibitory effect on ADP-mediated platelet
aggregations (16,17) and on prothrombinase activity (18).
Moreover, apoH may be involved in the metabolism of
triglyceride-rich lipoproteins as well as in the regulation of
haemostasis and in the clearance of apoptotic bodies,
mediating the phagocytic uptake of phosphatidylserine
containing liposomes by macrophages (19-21).
The only generally accepted property of apoH is its affinity
for negatively charged phospholipids and its physiological
properties could all be explained by neutralization of anionic
phospholipids, regulating the exposure of negatively charged
phospholipids on cellular surfaces in contact with blood.
Referring to this aspect, Yan et al (22) have recently reported
an inhibiting, instead of enhancing, effect of apoH on liposome
uptake by hepatocytes, Kupffer cells and endothelial cells.
Moreover, the low affinity of apoH for natural membranes
exposing phosphatidylserine raises doubts about these apoH
functions (23).
ApoH has been extensively characterized at amino acid and
nucleotide levels from a number of species including human
(24-26), rat (27), mouse (28,29), dog (30), cattle (31-33) and
chimpanzee (34).
The presence of apoH protein was detected by immuno-
histochemistry at the syncytiotrophoblastic layer of normal
placental villous tissue, in liver, mostly in some hepatocytes
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adjacent to the centrolobular veins, and in the enterocytes of
jejunum and colon (35,36).
The expression of apoH mRNA was initially detected by
Northern blotting in human, rat and mouse liver and in two
liver-derived cell lines, HepG2 and Hep3B (30,37,38). More
recently apoH mRNA was found by RT-PCR on RNA
extracted from other tissues (intestine, placenta, foetal
astrocytes, lymphocytes) or cultured cells (transformed cell
lines) such as choriocarcinoma, hepatoma (36), colon adeno-
carcinoma (35), neuroblastoma, umbilical vein endothelial
cells (HUVEC, but not for Alvarado-de la Barrera, 39), astro-
cytoma, glioblastoma cells (40) and in monocytes (41).
In previous experiments (36) some of us suggested a
functional regulation of the expression of apoH in liver. More
recently it has been demonstrated that ApoH gene expression
is strictly related to the proliferative status of hepatic cells
and that this protein could play a role in maintaining the
vitality of liver cells when exposed to different stress factors
such as regeneration after partial hepatectomy or growth
factor depletion (42).
To shed some light on transcriptional regulation and on
apoH synthesis sites we investigated the presence of apoH
mRNA in several normal rat tissues by RT-PCR and non-
radioactive in situ hybridization techniques.
Materials and methods
Animals. Wistar rats (Stefano Morini, San Polo d'Enza, Italy)
were housed in our institutional care facility under direction
of a licensed veterinary. Procedures involving animals were
conducted according to the European Community Council
Directory 86/609, OJL 358 1, 12 December 1987. Wistar rats
were sacrificed by cervical dislocation after ether anaesthesia.
Tissues were removed and frozen immediately in liquid
nitrogen for RNA extraction or placed in 4% formaldehyde
in PBS for in situ hybridization (ISH).
Probe. The probe used in Northern blotting, Southern blotting
and ISH was a PCR-amplified 550-bp fragment of human
apoH cDNA (from 60 to 610, GenBank accession no.
NM_000042), cloned in pPCR-Script-Amp vector.
Northern blotting and RT-PCR. Total RNA was extracted
from frozen samples using the phenol-guanidine thiocyanate
method described by Chomczynski and Sacchi (43). Total
RNA concentration was determined by measuring absorbance
at 260 nm and the quality was detected by electrophoresis of
the samples on formaldehyde agarose gel. After electro-
phoresis, fractionated RNA (10 μg) was transferred to nylon
membranes (Hybond X; Amersham Pharmacia Biotech).
The filter was hybridized to random priming labeled (·-32P)
deoxycytidine triphosphate (dCTP) human apoH specific
probe, according to standard methods, with stringency washes
of 0.2X SSC, 0.5% sodium dodecyl sulphate, at 65˚C. After
washing, the filters were exposed to autoradiographic film
(Hyperfilm; Amersham Pharmacia Biotech) with intensifying
screens at -70˚C.
RT-PCR experiments were carried out with the
AccessQuick RT-PCR System (Promega) using 1 μg of
total RNA. The cDNA primers were ApoRat3: 5'-TTCC
TCTGCCATGTTGCTATTGC-3' (from 41 to 63) and
ApoRat4R: 5'-CCTTGGTACAACACGGTGGC-3' [from
693 to 674; GenBank accession no. X15551 (27)]. Although
a 653-bp fragment was expected (see Results), a 797-bp
product was generated by using these primers. PCR was
performed on a (Eppendorf) thermal cycler under the following
conditions: 94˚C (4 min); 94˚C (30 sec), 55˚C (30 sec), 72˚C
(45 sec) (35 cycles); and 72˚C (5 min).
Aliquots of 10 μl of amplified products were resolved by
electrophoresis in 1.5% agarose gel and stained with ethidium
bromide. Following electrophoresis, samples were trans-
ferred onto nylon membranes. The filters were hybridized to
random priming labeled (·-32P)-(dCTP) human apoH cDNA
probe, washed at stringent conditions (0.2xSSC, 0.5%SDS,
65˚C) and exposed for different times to X-ray film.
The RT-PCR product obtained from liver RNA was
automatically sequenced (ABI PRISM 3100 system) using
primers ApoRat3, apoH5R (CATCGCATGTTGTGGCAAA
CATT), apoH3R (CTTCCTCAGTGCACTTGGCAG) and
ApoRat4R.
In situ hybridization. Preventively formaldehyde-fixed tissues
were dehydrated, cleared in xylene, infiltrated and embedded
in paraffin. Sections of 7 μm thick were air dried on poly-L-
lysine-coated glass slides.
Digoxigenin-(DIG)-labeled cRNA antisense and sense
probes were generated by in vitro transcription, according to
the DIG-RNA labeling procedure (Roche), using human
apoH cDNA plasmid clone linearized with DraII or HindIII
restriction enzymes and T3 or T7 RNA polymerases (Promega)
respectively. Integrity and concentration of probes were
assessed by agarose gel electrophoresis and by comparative
dot blotting together with a DIG-labeled standard template of
known concentration.
Hybridization was performed according to the protocol of
Moorman et al (44) with the following modification: pre-
hybridization and hybridization temperatures were 65˚C
because of probe heterology.
Negative controls were carried out by substituting an anti-
sense with a sense probe or by RNase A treatment (40 μg/ml
at 37˚C for 30 min) prior to hybridization. The probe was
detected with alkaline phosphatase-coupled anti-DIG antibody
followed by an NBT/BCIP colour reaction.
Results
Since expression data on apoH mRNA derive mainly from
RT-PCR experiments performed on transformed cell lines or
immunohistochemical experiments showing the localization
of the protein, we tested the presence of apoH transcript in
normal rat tissues with RT-PCR and in situ hybridization
assays.
To perform Northern blot analyses we extracted total RNA
from several rat tissues (liver, spleen, lung, kidney, small
intestine, heart, prostate, skeletal muscle, stomach). Because
human and rat transcripts share 83% homology (26), we used
as a probe a human apoH cDNA fragment, corresponding to
the region coding for aa 68-191 of the human protein, cloned
in pPCR Script-Amp vector. Using this method we identified
the apoH messenger (of approximately 1200 nucleotides) only
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in liver RNA (Fig. 1) as expected from previously published
data (27).
For an accurate investigation of the synthesis of apoH
transcript in other tissues we utilized the more sensitive
RT-PCR technique. We evaluated the apoH mRNA expression
in the same tissues that we used for Northern blot experiments
and, as a further positive control, in human hepatoma cell
line HepG2, which is known to express high apoH mRNA
levels (35,36). The primers utilized in these experiments
were constructed from highly conserved sequences in human
and rat cDNA and were intentionally designed so that one
hybridized to the first exon and the other to the seventh exon,
in order to point out an eventual DNA genomic contamination.
The ethidium bromide staining of the gel showed the
RT-PCR products obtained from rat liver and kidney RNA
samples, as well as the human HepG2 RNA sample (Fig. 2A).
As assumed, the RT-PCR product obtained from human
HepG2 RNA was 797 bp long, the RT-PCR products from
rat RNA were the same size, although according to published
data (27) 652 bp fragments were expected.
The RT-PCR product obtained from liver RNA was then
purified from agarose gel and automatically sequenced using
an ABI PRISM 3100 system (GenBank accession no.
AM071386).
Sequence analysis, performed using the BLAST (Basic
Local Alignment Search Tool) server (http://www.ncbi.nlm.
nih.gov/BLAST/), confirmed that the product contained the
murine apoH mRNA sequence, previously published (27),
and also a 145-bp insert, located between nucleotide positions
71-72, as occurs in human and in other mammalian species
(26,28,30,33).
Sequence analysis using rat BLAT search (http://genome.
cse.ucsc.edu/cgi-bin/hgBlat) gave the maximum identity
(100%) with position 97739499-97752117 of chromosome 10,
band 10q32.1 corresponding to the ApoH gene. The sequence
was also compared with human cDNA and genomic sequences,
demonstrating an 81% homology and that intron positions
are conserved (45,46).
Southern blot analysis of RT-PCR-amplified products
allowed us to detect apoH cDNA also in brain, small intestine,
heart, and, after a five-day exposure, in spleen, stomach and
prostate samples (Fig. 2B).
Thus, the apoH specific transcript was detectable in a
wide variety of tissues with a prevalence of expression in
liver and kidney, as well as in intestine, heart and brain.
Comparatively lower levels of expression were evident in
spleen, stomach and prostate. Transcripts, instead, were
below detectable levels in the skeletal muscle and lung.
To determine the regional distribution of apoH mRNA,
we performed in situ hybridization on paraffin embedded
sections of tissues expressing the ApoH gene at a higher level:
liver, kidney, intestine and heart. A human apoH-specific
antisense digoxigenin-labeled riboprobe was used. In line
with the RT-PCR results, we found apoH mRNA in all tested
tissues.
In liver (Fig. 3A and C), apoH mRNA was strongly
expressed in the columnar epithelium lining the bile duct of
portal canals (cholangiocytes), but not in the cells lining the
intrahepatic artery, the portal vein or the lymphatic vessel.
No staining was observed in the endothelial cells of central
veins. In addition, besides a low expression detectable within
the liver parenchyma, we observed higher apoH messenger
expression in individual hepatocytes (especially in the nuclei)
and also in Kupffer cells (Fig. 3D).
In kidney (Fig. 3H) the expression was evident in the
cortical layer and, in particular, in the absorptive cells of
proximal convoluted tubules. No staining was observed in
cells of the renal corpuscles.
These results indicated that cholangiocytes and collecting
duct epithelial cells were the major sites of apoH production
in liver and kidney, respectively.
In the jejunum region of the small intestine (Fig. 3E and F)
apoH mRNA was localized in the cells of the lamina propria,
which forms the core of villi and surrounds the intestinal
glands beneath the muscolaris mucosae, but not in the intestinal
mucosa. Rare smooth muscle cells appeared stained.
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Figure 1. (A) Northern blotting of total rat RNA extracted from several
normal tissues hybridized with a 32P-labeled human apoH probe: the
transcript is detected only in liver. (B) Ethidium bromide staining of the gel
showing the 28S rRNA bands: the sample amounts are comparable. Br,
brain; Hea, heart; Lu, lung; St, stomach; Int, small intestine; Sp, spleen; Ki,
kidney; Pr, prostate; Li, liver; Mu, skeletal muscle.
Figure 2. Detection of apoH mRNA by single-step RT-PCR followed by
Southern blot analysis, performed on the same RNAs as the Northern
blotting and, as a positive control, on human HepG2 cell RNA. (A) Ten
microliters of amplified product was resolved by electrophoresis in a 1.5%
agarose gel and stained with ethidium bromide. Amplified fragments were
797 bp long, both in rat and human samples (arrow). Molecular markers
(M=123 bp ladder) are shown. The apoH transcript is evident in kidney,
liver and HepG2. (B) RT-PCR products were analyzed by Southern blot
technique using the same specific apoH probe as for the Northern blotting.
The exposure times were 10 min, 1 day and 5 days for the different samples
as indicated in the figure. Note that the high stringency conditions used in
this experiment favour probe hybridization with human RT-PCR product.
The apoH transcript is detectable in liver, kidney, brain, heart, small
intestine, spleen, prostate, stomach, other than HepG2 cells (Hep). For
abbreviations see Fig. 1.
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In the heart (Fig. 3G), the probe appeared to hybridize
within all cardiomyocytes, mostly in the cytoplasm around
the nucleus (perinuclear labeling).
On all tested tissues no signal was observed in sections
hybridized with the apoH sense strand (Fig. 3B) or in sections
that had been treated with ribonuclease (not shown).
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Figure 3. Distribution of apoH transcripts in different normal rat tissues detected by in situ hybridization, using digoxigenin-labeled cRNA specific probe. A
dark blue to purple precipitate indicates the presence of apoH transcript. (A) Liver portal canal showing strong staining in bile duct epithelium. (B) Parallel
section to A: no signal was detected when sense probe for apoH was used. (C) Higher magnification of a selected region of A, showing localization of apoH
mRNA in cholangiocytes lining the bile duct (bd). Note the absence of reaction in both the hepatic artery (ha) and the portal vein (pv) endothelium as well as
in the lymphatic vessel (lv). (D) ApoH transcript was also detected in some nuclei of hepatic cells (black arrow) and in Kupffer cells (white arrow). (E) In
jejunum the transcript is localized in the core of villi; (F) higher magnification showing exclusive localization of apoH mRNA in lamina propria cells and not
in epithelial cells. (G) In the heart mRNA is present in all cardiomyocytes and is localized especially in the perinuclear zone (arrow). (H) Kidney cortical
region: the ApoH gene is expressed in proximal convoluted tubule cells (black arrow in higher-resolution inset) and no reaction product is detectable in renal
corpuscles (white arrow in higher-resolution inset). Original magnification: A, B, E, x20; C, D, F, G, H, x40; H insert, x100. 
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Discussion
At present, one of the most important factors in understanding
the physiologic role of the apoH protein is knowing its synth-
esis tissues. To shed light on this issue, we analyzed several
normal rat tissues by different techniques. We began our
studies on ApoH expression by performing Northern blot
analysis on total RNAs, using a human apoH cDNA probe:
this approach confirmed that the liver is the major site of
biosynthesis for apoH (37). 
The RT-PCR experiments that we performed on the same
total RNAs showed that, besides a strong expression in liver,
the ApoH gene was expressed also in kidney. By subsequent
Southern blot hybridization of these RT-PCR products with a
human apoH probe, it was possible to detect the messenger
in the small intestine, brain and also, at lower levels, in spleen,
stomach and prostate. Moreover, the rat cDNA fragment had
the same length as the human cDNA fragment. In fact,
sequence analysis of the amplified RT-PCR product obtained
from rat liver RNA revealed that the rat fragment which we
amplified contained 145 bp more than that reported in
previously published data (27) and therefore there is a higher
similarity between rat and other mammalian apoH cDNA
than previously thought.
Finally, we determined the localization of the apoH
transcript by performing non-radioactive in situ hybridization
experiments on tissues with a higher prevalence of apoH
transcript, as highlighted by Northern blot and RT-PCR
assays. The results obtained show a high presence of apoH
messenger especially in the epithelial cells of the bile duct in
liver and of the proximal tubules in kidney.
This specific localization of apoH mRNA could be
consistent with a pre-eminent role of apoH in the process by
which cholangiocytes and tubular cells reabsorb lipid particles
from the ductal bile and the glomerular filtrate, respectively.
It is in fact known that the organic and inorganic components
of bile may be significantly modified by an array of absorptive
mechanisms on the apical membrane of cholangiocytes. In
the same way, glomerular filtrate is continuously reabsorbed
by proximal tubule cells (and megalin is a good candidate as
LDL-family receptor; 47).
Moreover, apoH protein was already identified in several
parts of the kidney suggesting that it was filtered by the
glomerulus and then reabsorbed (48). Our results indicate
that apoH is produced also by the same tubular epithelial cells,
thus explaining the massive urinary presence of this protein
in patients with several renal tubular diseases, including adult
Fanconi syndrome.
The presence of apoH mRNA in the lamina propria cells
of jejunum (probably lymphocytes and macrophages), together
with the expression in Kuppfer cells, is in agreement with the
role of apoH as opsonin, mediating the phagocytic uptake of
liposomes and of apoptotic membranes containing anionic
phospholipids (49). Hence, phagocytes do not only recognize
and take up apoptotic cell remnants showing apoH on their
surface, but they also synthesize apoH. The need for producing
this protein is probably due to the low affinity of apoH for
natural membranes showed by Bevers et al (23), which could
require a high concentration of the protein in the cellular
microenvironment.
Although it is generally accepted that the protein is present
on different endothelial cell membranes (50,51), the results
on apoH mRNA expressed by endotheliocytes are conflicting
(39,40). Moreover, we did not observe apoH transcripts in
endothelial cells. On the other hand, apoH can adhere on
the cell membrane through interaction between the cationic
phospholipid binding site in the fifth domain and the anionic
structures on the cell membrane or it can be recognized as a
ligand for a receptor (probably annexin II-toll-like receptor,
TLR-4). Furthermore, in antiphospholipid syndrome patients,
many reports indicate that, when present, anti-ß2GPI antibodies
may recognize the molecule on the endothelial cells and that,
once bound, they might activate them inducing a proinflam-
matory and a procoagulant phenotype (reviewed in ref. 52).
Finally, with regard to the role of apoH in triglyceride-rich
lipoprotein metabolism, our experiments showed that, at least in
jejunum, enterocytes did not synthesize apoH. Thus, given that
immunohistochemical studies detected the protein in these cells,
we have to suppose that jejunum enterocytes take up apoH
from plasma to assemble new lipid particles or, more likely,
from the apoH producing cells which are present in the villi.
Our results collectively illustrate that the sites of apoH
synthesis are often different to protein accumulation sites:
for example, in liver the protein is localized mostly in the
hepatocytes adjacent to the centrolobular veins (35) whereas
the mRNA is expressed in few hepatocytes which are probably
proliferating cells, because it is known that in hepatocytes
and in HepG2 apoH expression depends on their proliferative
rate (42).
Our results suggest also that the ApoH gene is expressed
in cells where the protein has a direct role, for example in
the recovery of liposome particles by receptor-mediated
endocytosis (cholangiocytes, proximal tubule cells and also
macrophages) or when the lipid need arises for metabolic
(cardiomyocytes) or proliferative (hepatocytes) processes.
For normal lipid metabolism and/or transport (transcytosis)
instead, cells (endotheliocytes and enterocytes) could absorb
and accumulate the protein (probably in combination with
lipoprotein) from blood or from nearby cells.
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